Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users
July 31 2023 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
successful launch of its optical genome mapping (OGM) roadshow,
Bionano TOUR, a series of regional customer-led events that
showcase the latest advancements to the OGM workflow and
demonstrate applicable research applications.
Bionano TOUR provides an immersive in-person experience for
attendees, combining informative demonstrations of the OGM
workflow, the Ionic® system and VIA™ software from internal Bionano
experts with presentations from current OGM users who have
implemented the workflow for research in hematological
malignancies, genetic disease, cell bioprocessing, and other
applications. By bringing together industry experts, thought
leaders, and technical product specialists, the event serves as a
platform for attendees to explore ways OGM might provide new
cytogenetic insights in their research and address critical gaps
that are left unanswered by other genome analysis products.
Moreover, TOUR acts as a catalyst for building strong, locally
supported OGM communities, allowing users to connect with their
peers and helping to build relationships amongst current and
potential customers.
"We are really pleased to see how enthusiastic scientists and
clinicians are about TOUR, which has visited 8 U.S. cities so far
with more planned for this fall," said Erik Holmlin, Ph.D.,
president and chief executive officer of Bionano. "Bionano
Symposium, which gathers the global community of OGM users and
prospective users in a virtual event that lasts for a week in
January, has been enormously successful in showing how the
community uses OGM in their research. TOUR takes that same level of
in-depth OGM experience with users to live, in-person events
offering engagement with OGM experts to existing users. TOUR also
provides the opportunity for new potential OGM users to learn what
OGM is all about."
For more information on upcoming events, visit
www.bionano.com/tour-2023.
About Bionano
Bionano is a provider of genomic analysis solutions that can
help reveal answers to challenging genetic questions. Our mission
is to transform the way the world sees the genome through optical
genome mapping (OGM). Our OGM solutions allow scientists and
clinical researchers the ability to see and discover structural
variations in a way unmatched by traditional cytogenetic
techniques. Our products additionally include an industry-leading,
platform-agnostic software solution, which integrates OGM,
next-generation sequencing and microarray data in one consolidated
view, and nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. Our Lineagen, Inc.,
d/b/a Bionano Laboratories, business provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities. To
learn more, visit bionano.com and connect with us
on Twitter, LinkedIn, Instagram,
and YouTube.
Unless specifically noted otherwise, Bionano products are
provided for Research Use Only. Not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “can,” “might,” “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the potential of TOUR to drive adoption of our OGM workflows or
other genomic solutions; the potential of our OGM workflows or
other genomic solutions to be useful in research applications such
as hematological malignancies, genetic disease, and cell
bioprocessing; the ability of our OGM workflows and other genomic
solutions to offer new insights and address critical gaps left
unanswered by other genome analysis products; and execution of our
stated strategies and plans. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of geopolitical and macroeconomic developments, such as
recent and potential future bank failures, the ongoing
Ukraine-Russian conflict, and related sanctions, and the COVID-19
pandemic, on our business and the global economy; the failure TOUR
to drive adoption of our OGM workflows and other genomic solutions;
the failure of our OGM workflows or other genomic solutions to be
useful in research applications such as hematological malignancies,
genetic disease, and cell bioprocessing; the failure of our OGM
workflows and other genomic solutions to offer new insights and
address critical gaps left unanswered by other genome analysis
products; execution of our stated strategies and plans; general
market conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts and our ability to
continue as a “going concern”; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2022
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact: Erik Holmlin, CEO Bionano
Genomics, Inc. +1 (858) 888-7610 eholmlin@bionano.com
Investor Relations: David Holmes Gilmartin
Group +1 (858) 888-7625 IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jul 2023 to Jul 2024